To facilitate clinical trials of disease-modifying therapies for Alzheimer’s disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease 1 , 2 , …

Visual disturbance, hypertension, convulsions, and unconsciousness developed in a 70-year-old
man after cisplatin chemotherapy and upper-limb amputation for osteosarcoma. MR …

Recent cerebral blood flow (CBF) and glucose consumption (CMRglc) studies of Parkinson’s
disease (PD) revealed conflicting results. Using simulated data, we previously …

We investigated the relative differences in dopaminergic function through the whole brain in
patients with Parkinson’s disease without dementia (PD) and with dementia (PDD) using 6‐[ …

Alzheimer’s disease (AD) is the most common and devastating dementia. Simple and
practical biomarkers for AD are urgently required for accurate diagnosis and to facilitate the …

Biomarkers useful for the predementia stages of Alzheimer’s disease are needed.
Electroencephalography and magnetoencephalography (MEG) are expected to provide potential …

To determine the characteristics of cerebral glucose metabolism in Parkinson's disease
patients with visual hallucinations, group comparison studies using [ 18 F]fluorodeoxyglucose …

Amyloid-β (Aβ) deposition is known to starts decades before the onset of clinical symptoms
of Alzheimer’s disease (AD), however, the detailed pathophysiological processes underlying …

Objective: Using 6-[ 18 F]fluoro-l-dopa (FDOPA) and [ 18 F]fluorodeoxyglucoce (FDG) positron
emission tomography (PET), multiple regression analyses were performed to determine …

Background: 18F-FDG-PET is defined as a biomarker of neuronal injury according to the
revised National Institute on Aging–Alzheimer’s Association criteria. Objective: The objective of …